Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Hims & Hers Health

Strategic Insights

— 1 min read

Pomerantz LLP has announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on allegations of securities fraud and other unlawful business practices. The lawsuit concerns the company's promotion and sale of compounded drugs under the guise of "personalization." Investors who purchased Hims & Hers securities during the class period have until August 25, 2025, to request to be appointed as Lead Plaintiff.

Key Takeaways:

  • A class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) alleging securities fraud and other unlawful business practices.
  • The lawsuit concerns the company's promotion and sale of compounded drugs under the guise of "personalization."
  • On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk, which included the sale of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.
  • On June 23, 2025, Novo Nordisk issued a press release announcing the termination of its partnership with Hims & Hers due to the company's deceptive promotion of illegitimate, knockoff versions of Wegovy.
  • The press release stated that Hims & Hers had failed to adhere to the law, leading to patient safety concerns.
  • Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.
  • Pomerantz LLP has recovered numerous multimillion-dollar damages awards on behalf of class members in the past.
  • Hims & Hers' collaboration with Novo Nordisk was part of the company's effort to expand its product offerings and reach a wider audience.

Statistics:

  • Hims & Hers' stock price fell by 34.63% due to the news of Novo Nordisk's termination of the partnership on June 23, 2025.
  • The lawsuit alleges that Hims & Hers engaged in securities fraud and other unlawful business practices.
  • Hims & Hers' collaboration with Novo Nordisk involved the sale of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.
  • Novo Nordisk's partnership with Hims & Hers was terminated due to patient safety concerns caused by the company's promotion of illegitimate, knockoff versions of Wegovy.

Sources:

  • Pomerantz LLP. "Pomerantz Announces a Class Action against Hims & Hers Health, Inc. and Certain Officers." (2025). Available at.
  • Novo Nordisk. "Novo Nordisk Terminates Partnership with Hims & Hers Due to Patient Safety Concerns." (2025). Available at.
  • Hims & Hers Health, Inc. "Hims & Hers Announces Collaboration with Novo Nordisk." (2025). Available at.

Read more